"Designing Growth Strategies is in our DNA"

Asia Pacific Multiple Sclerosis Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection {Intramuscular, Subcutaneous, and Intravenous}), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2023-2030

Last Updated: February 03, 2025 | Format: PDF | Report ID: FBI107929

 

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Prevalence of Multiple Sclerosis - For Key Countries
    2. Patent Snapshot, Key Players
    3. Pipeline Analysis & R&D Investments
    4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
    5. Impact of COVID-19 on the Market
  5. Asia Pacific Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2019-2030
    1. Market Analysis, Insights and Forecast – By Drug Class
      1. Immunomodulators
      2. Immunosuppressants
      3. Interferons
      4. Others
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Injection
        1. Intramuscular
        2. Subcutaneous
        3. Intravenous
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
    4. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. China
      2. India
      3. Japan
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
  6. Competitive Analysis
    1. Asia Pacific Market Share Analysis
    2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
      1. Biogen
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      2. Teva Pharmaceutical Industries Ltd.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      3. Merck KGaA
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      4. Sanofi
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      5. Novartis AG
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      6. F. Hoffmann-La Roche Ltd.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      7. Pfizer Inc.
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      8. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      9. Bristol-Myers Squibb Company
        1. Overview,
        2. Products,
        3. SWOT Analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
Read Less

Figure 1:  Asia Pacific Multiple Sclerosis Drugs Market Revenue Breakdown (USD billion, %) by Country/Sub-region, 2022 & 2030

Figure 2:  Asia Pacific Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2022 & 2030

Figure 3:  Asia Pacific Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2022 & 2030

Figure 4:  Asia Pacific Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2022 & 2030

Figure 5:  Asia Pacific Multiple Sclerosis Drugs Market Value (USD billion), by Country/Sub-region, 2022 & 2030

Figure 6:  Asia Pacific Multiple Sclerosis Drugs Market Share (%), By Company

Table 1:  Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2019–2030

Table 2:  Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2030

Table 3:  Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Injection, 2019–2030

Table 4:  Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2030

Table 5:  Asia Pacific Multiple Sclerosis Drugs Market Revenue (USD billion) Forecast, by Country/Sub-region, 2019–2030

 

Asia Pacific Multiple Sclerosis Drugs Market Size, Share and Global Industry Trend Forecast till 2030
  • 2019-2030
  • 2022
  • 2019-2021
  • 109
Multi-report Purchase Plan
    A Customized Plan Will be Created Based on the number of reports you wish to purchase